Jan 09, 2020 / 07:00PM GMT
Salveen Jaswal Richter - Goldman Sachs Group Inc., Research Division - VP
Good afternoon, everyone. Thanks for joining us. I'm Salveen Richter, I cover the biotechnology sector on Goldman Sachs, and we're very pleased to have the CEO or Chief
(technical difficulty)
of bluebird with us, Nick Leschly.
Questions and Answers:
Salveen Jaswal Richter - Goldman Sachs Group Inc., Research Division - VPSo Nick, you have with us the evolution of bluebird over the last decade, and the company is a pioneer in the field of genomic medicine. So how does the company and industry today compare to your 10-year view from when you first started as CEO?
Nick Leschly - bluebird bio, Inc. - President, CEO & Director
Well, first, thanks, Salveen, for having me here. I appreciate it. And you're always good about asking questions that I'm not prepared to answer. So 10 years, long time. I tend to measure that. And now my kids are leaving me, going to college and things like that. So it's been a big run in that
Trustpilot
